Comparison of the renal response of bortezomib-based induction and conventional regimen in multiple myeloma patients with renal failure

Authors

  • Ahmet Sarici Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Emin Kaya Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Mehmet Ali Erkurt Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Ilhami Berber Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Lokman Hekim Tanriverdi Department of Medical Pharmacy, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Omer Faruk Bahcecioglu Department of Clinical Pharmacy, Faculty of Pharmacy, Inonu University, Malatya, Turkey
  • Selim Gok Department of Clinical Pharmacy, Faculty of Pharmacy, Inonu University, Malatya, Turkey
  • Irfan Kuku Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey

Keywords:

Bortezomib, chemotherapy, hematology, multiple myeloma, renal failure, vincristine

Abstract

Aim: Vincristine-doxorubicin-dexamethasone (VAD) was the commonly used first-line treatment for multiple myeloma (MM) patients with renal failure before bortezomib entered clinical practice. In this trial, we aimed to compare the effect of VAD and bortezomib-cyclophosphamide-dexamethasone (VCD) chemotherapy regimens on improving kidney function in MM patients with renal failure.
Materials and Methods: The records of MM patients in our center between January 2010 and February 2020 were retrospectively analyzed. Patients who received VAD or VCD as a first treatment chemotherapy protocol and whose initially estimated glomerular filtration rate (eGFR) was 50 mL/min/1.73 m2 and below were included in the study. Patients were divided into two groups according to the chemotherapy regimens they received.
Results: Sixty one MM patients (VAD: 26, VCD: 35) were included in the study. No significant difference was found between the VAD and VCD groups when the baseline, 1st and 2nd month eGFRs were compared (p>0.05). Overall renal response rate (at least minor response) in the VCD group at the end of the 1st month were higher than in the VAD group (p=0.002). Also, renal response rate in the VCD group at the end of the 2nd month were higher than in the VAD group (p=0.033).
Conclusion: In MM patients with renal insufficiency, overall renal response rates have increased with the use of VCD instead of VAD as a standard induction regimen.

Downloads

Download data is not yet available.

Downloads

Published

2021-10-20

How to Cite

Sarici, A., Kaya, E., Erkurt, M. A., Berber, I., Tanriverdi, L. H., Bahcecioglu, O. F., Gok, S., & Kuku, I. (2021). Comparison of the renal response of bortezomib-based induction and conventional regimen in multiple myeloma patients with renal failure. Annals of Medical Research, 28(10), 1824–1829. Retrieved from https://annalsmedres.org/index.php/aomr/article/view/3934

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 > >>